Tralokinumab: Exploring the Possibility of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a novel therapy for atopic dermatitis. This humanized antibody targets IL-13, a https://www.targetmol.com/compound/tralokinumab